New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZATM, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients. DURLAZA is now commercially available for physicians and their patients.
You are here
New Haven Pharmaceuticals, Inc. today announced President and CEO Patrick Fourteau was named a 2015 Entrepreneur of the Year award by Connecticut United for Research Excellence (CURE). Fourteau was recognized at a ceremony in Connecticut on Dec. 8th.
New Haven Pharmaceuticals, Inc. today announced new study data that shows the company’s FDA-approved drug DURLAZA™ delivers sustained antiplatelet control for a full 24-hour period in high-risk patients.